Jump to content


E-Newsletter Signup Like us on Facebook Sign Up For Our e-Newsletter
Photo

Cogane


  • Please log in to reply
3 replies to this topic

#1 jake70

jake70

    Newbie

  • Members
  • Pip
  • 7 posts

Posted 18 February 2013 - 03:03 PM

Hello Doctors,

I am wondering how the phase II trial of Cogane ended up. I keep searching the internet for results, but it's all old information.

Regards,
Jacob

#2 Dr. Okun

Dr. Okun

    Advanced Member

  • Ask the Doctor Moderators
  • PipPipPip
  • 4,497 posts
  • LocationUniversity of Florida

Posted 19 February 2013 - 08:08 PM

So far we have heard the safety was ok, but we await more data and publications.

Michael S. Okun, M.D.
Author of the Amazon Bestseller Parkinson's Treatment: 10 Secrets to a Happier Life
National Medical Director | NPF
UF Center for Movement Disorders & Neurorestoration
Read More about Dr. Okun at: http://movementdisor...hael-s-okun-md/
or Visit Parkinson's Disease treatment and research blogs at:
NPF's What's Hot in Parkinson's disease
or his parkinsonsecrets.com blog for treatment tips


#3 cbrf1wr

cbrf1wr

    Newbie

  • Members
  • Pip
  • 2 posts

Posted 19 February 2013 - 09:34 PM

This was posted on one of the other forums. Looks official.



FEB 18 2013 PHYTOPHARM SHARE PRICE DROPPED 87% in early morning trading…

Professor C Warren Olanow, Professor of Neurology and Neuroscience at Mount Sinai Medical School and Co-chief Investigator for the study commented:

“This is disappointing news for the Parkinson disease community… The company is to be congratulated for carrying out this important study in such a high quality manner. Sadly, the results are negative.”

Commenting on these results, Tim Sharpington, CEO said: “We are naturally disappointed with the outcome of this study of Cogane™ in patients with Parkinson’s disease. Cogane had demonstrated encouraging efficacy in a wide range of industry standard pre-clinical models but this promise has not translated into clinically meaningful efficacy in this study. I would like to thank the investigators who conducted the trial, our collaborators and especially the patients who participated in the study…”

Analyst Dr Paul Cuddon at Peel Hunt said:
… “the result was a conclusive failure for Phytopharm's key asset”, and he attributed no value to the group's remaining pipeline of drugs.

“The comprehensive nature of the failure raises questions over the relevance of the pre-clinical models used, and the size/expense of the trial that was required to prove that Cogane was futile. Ultimately this outcome should have been reached at a lesser loss ,...”

“Reaching this point sooner remains a key challenge for the pharmaceutical industry. Until companies are better able to select for specific genetically defined patients for targeted drugs, UK pre-revenue drug development companies will remain a lottery. “

#4 Dr. Okun

Dr. Okun

    Advanced Member

  • Ask the Doctor Moderators
  • PipPipPip
  • 4,497 posts
  • LocationUniversity of Florida

Posted 20 February 2013 - 03:54 PM

Thank you for posting. You beat me to the news on Cogane.

Michael S. Okun, M.D.
Author of the Amazon Bestseller Parkinson's Treatment: 10 Secrets to a Happier Life
National Medical Director | NPF
UF Center for Movement Disorders & Neurorestoration
Read More about Dr. Okun at: http://movementdisor...hael-s-okun-md/
or Visit Parkinson's Disease treatment and research blogs at:
NPF's What's Hot in Parkinson's disease
or his parkinsonsecrets.com blog for treatment tips





0 user(s) are reading this topic

0 members, 0 guests, 0 anonymous users